Research company Stayble Therapeutics has convened an extraordinary general meeting on May 7 to decide on voluntary liquidation, or alternatively, continued operations.
The company, which develops injectable treatments for chronic back pain, has for some time unsuccessfully sought partnerships and financing to advance the STA363 project. The board is therefore proposing liquidation with the aim of selling intellectual property assets to the highest bidder.
Interest has been shown by several global players and due diligence has been completed without issues, but deals have failed to materialize due to factors including the early stage of development, strategic priorities, and insufficient investment size.
To…